LXRX vs. ARMP

Last updated Apr 1, 2026

Compare and contrast key facts about Lexicon Pharmaceuticals, Inc. (LXRX) and Armata Pharmaceuticals Inc. (ARMP).

Performance

LXRX vs. ARMP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Lexicon Pharmaceuticals, Inc. (LXRX) and Armata Pharmaceuticals Inc. (ARMP). The values are adjusted to include any dividend payments, if applicable.

LXRX vs. ARMP - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
LXRX Lexicon Pharmaceuticals, Inc.	35.65%	55.72%	-51.73%	-19.90%	-51.52%	15.20%	-17.59%	-37.50%	-32.79%	-28.56%
ARMP Armata Pharmaceuticals Inc.	63.06%	239.46%	-42.90%	161.29%	-77.37%	83.59%	-8.16%	12.53%	-79.57%	-77.05%

Fundamentals

EPS LXRX : -$0.19 ARMP : -$4.80
PS Ratio LXRX : 8.00 ARMP : 57.24
Total Revenue (TTM) LXRX : $70.86M ARMP : $6.48M
Gross Profit (TTM) LXRX : $44.68M ARMP : $5.00M
EBITDA (TTM) LXRX : -$48.31M ARMP : -$58.74M

Returns By Period

In the year-to-date period, LXRX achieves a 35.65% return, which is significantly lower than ARMP's 63.06% return. Over the past 10 years, LXRX has outperformed ARMP with an annualized return of -18.78%, while ARMP has yielded a comparatively lower -32.31% annualized return.

LXRX

• 1D: 3.31%
• 1M: 6.12%
• YTD: 35.65%
• 6M: 15.56%
• 1Y: 238.54%
• 3Y*: -13.73%
• 5Y*: -23.28%
• 10Y*: -18.78%

ARMP

• 1D: 19.21%
• 1M: -4.83%
• YTD: 63.06%
• 6M: 243.62%
• 1Y: 601.37%
• 3Y*: 83.03%
• 5Y*: 16.66%
• 10Y*: -32.31%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

LXRX vs. ARMP — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LXRX

LXRX Risk / Return Rank: 92
LXRX Sharpe Ratio Rank: 95
LXRX Sortino Ratio Rank: 91
LXRX Omega Ratio Rank: 88
LXRX Calmar Ratio Rank: 94
LXRX Martin Ratio Rank: 90

ARMP

ARMP Risk / Return Rank: 98
ARMP Sharpe Ratio Rank: 98
ARMP Sortino Ratio Rank: 98
ARMP Omega Ratio Rank: 97
ARMP Calmar Ratio Rank: 99
ARMP Martin Ratio Rank: 99

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

LXRX vs. ARMP - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Lexicon Pharmaceuticals, Inc. (LXRX) and Armata Pharmaceuticals Inc. (ARMP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	LXRX	ARMP	Difference
Sharpe ratio Return per unit of total volatility	2.66	3.79	-1.13
Sortino ratio Return per unit of downside risk	3.03	4.73	-1.70
Omega ratio Gain probability vs. loss probability	1.37	1.60	-0.23
Calmar ratio Return relative to maximum drawdown	5.09	14.39	-9.30
Martin ratio Return relative to average drawdown	11.12	38.08	-26.96
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

LXRX vs. ARMP - Sharpe Ratio Comparison

The current LXRX Sharpe Ratio is 2.66, which is comparable to the ARMP Sharpe Ratio of 3.79. The chart below compares the historical Sharpe Ratios of LXRX and ARMP, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	LXRX	ARMP	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.66	3.79	-1.13
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.24	0.15	-0.39
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.19	-0.29	+0.09
Sharpe Ratio (All Time) Calculated using the full available price history	-0.18	-0.23	+0.05

Correlation

The correlation between LXRX and ARMP is 0.08, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

LXRX vs. ARMP - Dividend Comparison

Neither LXRX nor ARMP has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

LXRX vs. ARMP - Drawdown Comparison

The maximum LXRX drawdown since its inception was -99.91%, roughly equal to the maximum ARMP drawdown of -99.98%. Use the drawdown chart below to compare losses from any high point for LXRX and ARMP.

Drawdown Indicators

	LXRX	ARMP	Difference
Max Drawdown Largest peak-to-trough decline	-99.91%	-99.98%	+0.07%
Max Drawdown (1Y) Largest decline over 1 year	-34.09%	-37.22%	+3.13%
Max Drawdown (5Y) Largest decline over 5 years	-95.25%	-85.70%	-9.55%
Max Drawdown (10Y) Largest decline over 10 years	-98.48%	-99.84%	+1.36%
Current Drawdown Current decline from peak	-99.53%	-99.79%	+0.26%
Average Drawdown Average peak-to-trough decline	-93.16%	-82.58%	-10.58%
Ulcer Index Depth and duration of drawdowns from previous peaks	15.60%	14.40%	+1.20%

Volatility

LXRX vs. ARMP - Volatility Comparison

The current volatility for Lexicon Pharmaceuticals, Inc. (LXRX) is 16.82%, while Armata Pharmaceuticals Inc. (ARMP) has a volatility of 32.05%. This indicates that LXRX experiences smaller price fluctuations and is considered to be less risky than ARMP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	LXRX	ARMP	Difference
Volatility (1M) Calculated over the trailing 1-month period	16.82%	32.05%	-15.23%
Volatility (6M) Calculated over the trailing 6-month period	60.45%	104.47%	-44.02%
Volatility (1Y) Calculated over the trailing 1-year period	92.44%	160.36%	-67.92%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	97.46%	112.19%	-14.73%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	96.87%	112.45%	-15.58%

Financials